IGCS 2024 LBA Release

We are pleased to announce that after revising the current embargo policy, the titles of the IGCS 2024 Late-Breaking Abstracts are now available via the interactive program. This decision was made to help highlight the exceptional research submitted to the IGCS 2024 Meeting!

Please note that the full abstract bodies will remain under embargo and will be published via the IGCS 2024 website on the morning of the presentation day as previously communicated.

Wednesday, October 16, 2024

CADONILIMAB PLUS CHEMOTHERAPY ± BEVACIZUMAB AS 1L TREATMENT FOR PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER (R/M CC): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY (COMPASSION-16) Xiaohua Wu, China

ENGOT-EN11/GOG-3053/KEYNOTE-B21: PHASE 3 STUDY OF PEMBROLIZUMAB OR PLACEBO IN COMBINATION WITH ADJUVANT CHEMOTHERAPY WITH OR WITHOUT RADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED, HIGH-RISK ENDOMETRIAL CANCER Brian Slomovitz, USA

DURVALUMAB PLUS CARBOPLATIN/PACLITAXEL FOLLOWED BY DURVALUMAB WITH/WITHOUT OLAPARIB IN ENDOMETRIAL CANCER: EXPLORATORY ANALYSES OF BIOMARKER/HISTOLOGICAL HETEROGENEITY AND EFFICACY IN THE DUO-E MISMATCH REPAIR PROFICIENT SUBPOPULATION Shannon Westin, USA

DURVALUMAB PLUS CARBOPLATIN/PACLITAXEL FOLLOWED BY DURVALUMAB WITH/WITHOUT OLAPARIB FOR ENDOMETRIAL CANCER: MISMATCH REPAIR DEFICIENT AND/OR MICROSATELLITE INSTABILITY-HIGH SUBPOPULATION EFFICACY ANALYSES FROM THE DUO-E TRIAL Els Van Nieuwenhuysen, Belgium

BENMELSTOBART (TQB2450) ALONE OR COMBINED WITH ANLOTINIB IN PREVIOUSLY TREATED ADVANCED ENDOMETRIAL CANCER: UPDATED RESULTS FROM A MULTICOHORT, OPEN-LABEL, MULTICENTER PHASE II CLINICAL TRIAL TQB2450-II-08 Xiaohua Wu, China

KGOG3056/NIRVANA-R TRIAL: EFFICACY OF MAINTENANCE NIRAPARIB RECHALLENGE PLUS BEV ACCORDING TO MINIMAL RESIDUAL DISEASE (MRD) ASSESSMENT IN PATIENTS WITH PLATINUM-SENSITIVE, RECURRENT OVARIAN CANCER PREVIOUSLY TREATED WITH A PARP INHIBITOR Hyun-Woong Cho, Korea

A PHASE II TRIAL OF PEMBROLIZUMAB AND LENVATINIB IN RECURRENT OR PERSISTENT CLEAR CELL OVARIAN CARCINOMA (NCT05296512): STAGE 1 RESULTS Elizabeth Lee, USA

A PHASE 2 RANDOMIZED DOSE OPTIMIZATION TRIAL OF GOTISTOBART, A PH-SENSITIVE ANTI-CTLA-4, IN COMBINATION WITH PEMBROLIZUMAB IN PLATINUM-RESISTANT OVARIAN CANCER (PROC, PRESERVE-004/GOG-3081; NCT05446298) Joyce Barlin, USA

Thursday, October 17, 2024

ENGOT-CX11/GOG-3047/KEYNOTE-A18: PEMBROLIZUMAB OR PLACEBO WITH CHEMORADIOTHERAPY FOR NEWLY DIAGNOSED, HIGH-RISK, LOCALLY ADVANCED CERVICAL CANCER (LACC): RESULTS FROM INTERIM ANALYSIS 2 FOR PATIENTS ENROLLED IN ASIA Yang Xiang, China

ADJUVANT VACCINATION AGAINST HPV IN SURGICAL TREATMENT OF CIN LESIONS: RESULTS OF THE VACCIN-STUDY, A RANDOMISED PLACEBO-CONTROLLED TRIAL Ralf van de Laar, Netherlands

EFFICACY AND SAFETY OF AVUTOMETINIB ± DEFACTINIB IN RECURRENT LOW GRADE SEROUS OVARIAN CANCER: PRIMARY ANALYSIS OF ENGOT-OV60/GOG-3052/RAMP 201 Susana Banerjee, UK

Friday, October 18, 2024

NEOADJUVANT NIRAPARIB MONOTHERAPY IN HOMOLOGOUS RECOMBINATION DEFICIENCY-POSITIVE ADVANCED OVARIAN CANCER: A PROSPECTIVE, MULTICENTER, SINGLE-ARM, PHASE II STUDY (NANT) Qinglei Gao, China

RANDOMIZED, PHASE II/III STUDY OF PEGYLATED LIPOSOMAL DOXORUBICIN, BEVACIZUMAB, AND ATEZOLIZUMAB IN PLATINUM-RESISTANT OVARIAN CANCER (NRG-GY009): CLINICAL OUTCOMES BY PD-L1 AND T CELL INFILTRATION STATUS Dmitriy Zamarin, USA